Elevated plasma chitotriosidase activity in various lysosomal storage disorders

被引:173
|
作者
Guo, YF
He, W
Boer, AM
Wevers, RA
deBruijn, AM
Groener, JEMM
Hollak, CEM
Aerts, JMFG
Galjaard, H
vanDiggelen, OP
机构
[1] ERASMUS UNIV ROTTERDAM,DEPT CLIN GENET,3000 DR ROTTERDAM,NETHERLANDS
[2] UNIV NIJMEGEN HOSP,INST NEUROL,6500 HB NIJMEGEN,NETHERLANDS
[3] ERASMUS UNIV ROTTERDAM,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS
[4] LEIDEN UNIV,CLIN GENET CTR,LEIDEN,NETHERLANDS
[5] UNIV AMSTERDAM,ACAD MED CTR,DEPT BIOCHEM,1105 AZ AMSTERDAM,NETHERLANDS
关键词
D O I
10.1007/BF02436762
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recently a striking elevation of the activity of chitotriosidase, an endo beta-glucosaminidase distinct from lysozyme, was found in plasma from patients with Gaucher type I disease (McKusick 230800). Plasma chitotriosidase originates from activated macrophages and this elevation is secondary to the basic defect in Gaucher disease. To investigate the specificity of this phenomenon, we have investigated 24 different lysosomal storage diseases. In 11 different diseases increased chitotriosidase activity in plasma was found (in 28% of the patients). None of these diseases showed elevations as high as in Gaucher disease. Chitotriosidase was not significantly elevated in plasma from 20 different non-lysosomal enzymopathies or in plasma from patients with infectious diseases associated with hepatomegaly. The results show that marked elevation of chitotriosidase activity in plasma appears to be specific for Gaucher disease. The data further suggest that elevated levels of chitotriosidase activity in plasma from patients with unexplained diseases may be indicative for a lysosomal disorder.
引用
收藏
页码:717 / 722
页数:6
相关论文
共 50 条
  • [41] Treatment for Lysosomal Storage Disorders
    Sheth, Jayesh
    Nair, Aadhira
    CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (40) : 5110 - 5118
  • [42] Prevalence of lysosomal storage disorders
    Meikle, PJ
    Hopwood, JJ
    Clague, AE
    Carey, WF
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (03): : 249 - 254
  • [43] Sphingolipid lysosomal storage disorders
    Frances M. Platt
    Nature, 2014, 510 : 68 - 75
  • [44] Lysosomal Storage Disorders in the Newborn
    Staretz-Chacham, Orna
    Lang, Tess C.
    LaMarca, Mary E.
    Krasnewich, Donna
    Sidransky, Ellen
    PEDIATRICS, 2009, 123 (04) : 1191 - 1207
  • [45] Immunochemistry of lysosomal storage disorders
    Parkinson-Lawrence, Emma
    Fuller, Maria
    Hopwood, John J.
    Meikle, Peter J.
    Brooks, Doug A.
    CLINICAL CHEMISTRY, 2006, 52 (09) : 1660 - 1668
  • [46] Treatments for lysosomal storage disorders
    Lachmann, Robin
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2010, 38 : 1465 - 1468
  • [47] PSEUDODEFICIENCIES IN LYSOSOMAL STORAGE DISORDERS
    ZLOTOGORA, J
    BACH, G
    LANCET, 1985, 2 (8467): : 1296 - 1296
  • [48] Distinctly Elevated Chitotriosidase Activity in a Child with Congenital Andersen Disease (Glycogen Storage Disease Type IV)
    Schaenzer, A.
    Faas, D.
    Rust, S.
    Podskarbi, T.
    van Kuilenburg, A. B. P.
    Scarpa, M.
    Kunze, A.
    Marquardt, T.
    Hahn, A.
    KLINISCHE PADIATRIE, 2016, 228 (05): : 277 - 279
  • [49] Lysosomal storage disorders: The cellular impact of lysosomal dysfunction
    Platt, Frances M.
    Boland, Barry
    van der Spoel, Aarnoud C.
    JOURNAL OF CELL BIOLOGY, 2012, 199 (05): : 723 - 734
  • [50] Plasma chitotriosidase activity in patients with multiple sclerosis
    Comabella, Manuel
    Dominguez, C.
    Rio, Jordi
    Martin-Gallan, P.
    Vilches, A.
    Espejo, Carmen
    Montalban, Xavier
    MULTIPLE SCLEROSIS, 2008, 14 : S228 - S229